Prev Close | 24.08 |
Open | 24.42 |
Day Low/High | 23.53 / 26.16 |
52 Wk Low/High | 4.04 / 32.18 |
Volume | 1.37M |
Prev Close | 24.08 |
Open | 24.42 |
Day Low/High | 23.53 / 26.16 |
52 Wk Low/High | 4.04 / 32.18 |
Volume | 1.37M |
Exchange | NASDAQ |
Shares Outstanding | 56.26B |
Market Cap | 1.32B |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
A fresh look at all 17 ideas: the winners, the losers and the still to be determined.
I don't think MGNX has quite the same upside as IFRX, but a push above $23.50 should spur buying.
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.